Pancreatic endocrine cell indicating agent and utilization of same
AssigneeRiken
InventorsYasuyoshi Watanabe, Takeo Sako, Koki Hasegawa, Yousuke Kanayama, Yousuke Kataoka
Life of this patent
Estimating the term…
Abstract
A pancreatic endocrine cell indicating agent of the present invention includes a modified polypeptide in which a metal chelator binds only to an amino acid that is located at a site other than a somatostatin receptor-binding active site in a polypeptide selected from the group consisting of somatostatin and somatostatin analogs; and a radioactive metal nuclide held by the metal chelator. According to the present invention, it is therefore possible to provide a novel pancreatic endocrine cell indicating agent.
Claims14
A pancreatic endocrine cell indicating agent comprising:
- a modified polypeptide in which a metal chelator binds only to an amino acid that is located at a site other than a somatostatin receptor-binding active site in a polypeptide selected from the group consisting of somatostatin and somatostatin analogs;
- and
- a radioactive metal nuclide held by the metal chelator.
A pancreatic endocrine cell indicating agent comprising:
- a modified polypeptide in which DOTA (1,4,7,10-tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid) directly binds only to an amino acid that is located at an amino terminal of a polypeptide selected from the group consisting of somatostatin and somatostatin analogs;
- and
- a radioactive metal nuclide held by the DOTA.
Dependencies are inferred from the claim text.